C

	Application No.	Applicant(s)
	10/754,015	PARKER ET AL.
Notice of Allowability	Examiner	Art Unit
	Robert Sellers	1712
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.31	S (OR REMAINS) CLOSED in b) or other appropriate commining the commining of the commining o	n this application. If not included unication will be mailed in due course. THIS
1. $\boxtimes$ This communication is responsive to <u>the amendment after</u>	r Final rejection filed Novemb	per 7, 2006 which has been entered.
2. X The allowed claim(s) is/are 1,3-6,9-18,21-27,71-74,77,78,	80,81 and 93-96.	
3. ☐ Acknowledgment is made of a claim for foreign priority u  a) ☐ All b) ☐ Some* c) ☐ None of the:  1. ☐ Certified copies of the priority documents hav	re been received.	
2. Certified copies of the priority documents hav		
<ol> <li>Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)).</li> </ol>	ocuments have been receive	d in this hational stage application from the
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDON! THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		e a reply complying with the requirements
4. A SUBSTITUTE OATH OR DECLARATION must be subn INFORMAL PATENT APPLICATION (PTO-152) which give		
5. CORRECTED DRAWINGS (as "replacement sheets") mu	ıst be submitted.	
(a) 🔲 including changes required by the Notice of Draftsper	rson's Patent Drawing Review	w ( PTO-948) attached
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date	<b>-</b> •	
(b) ☐ including changes required by the attached Examiner Paper No./Mail Date	's Amendment / Comment o	r in the Office action of
Identifying indicia such as the application number (see 37 CFR each sheet. Replacement sheet(s) should be labeled as such in		
6. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT		
·		
Attachment(s)	E □ Notice of In	formal Patant Application
<ol> <li>Notice of References Cited (PTO-892)</li> <li>DNotice of Draftperson's Patent Drawing Review (PTO-948)</li> </ol>		formal Patent Application ummary (PTO-413),
	Paper No.	/Mail Date <u>20061129</u> .
3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	7. 🔀 Examiners	Amendment/Comment
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's	Statement of Reasons for Allowance
	9. 🔲 Other	<u> -</u>

Application/Control Number: 10/754,015 Page 2

Art Unit: 1712

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Douglas E. Winters on November 29, 2006.

The application has been amended as follows:

Page 17, line 4 and page 24, line 1 as well as claims 6 (line 5), 23 (lines 4-5), 72 (lines 4-5), 74 (line 11) and 81 (lines 4-5), amend "2,4,4-trimethylpenty-2 hydroperoxide" or "2,4,4-trimethylpeny-2-hydroperoxide" to --2,4,4-trimethylpentyl-2-hydroperoxide--.

Page 16, paragraph [0055], line 4 and page 21, paragraph [0082], lines 12-13 along with claim 14, line 3 and claim 25, lines 3-4, replace "1,3-BAC high reactive" with --1,3-bis(aminomethylcyclohexane amine)--.

The following is an examiner's statement of reasons for allowance:

2. The examiner's amendment hereinabove corrects the designation of the hydroperoxide to include the letter "I" in the moiety "trimethylpenty" [emphasis added] and chemically identifies acronym "BAC" in the 1,3-BAC highly reactive cycloaliphatic diamines as described on page 16, paragraph [0057], lines 5-6 of the specification.

Application/Control Number: 10/754,015 Page 3

Art Unit: 1712

3. The amendment after Final rejection filed November 7, 2006 has incorporated into independent claims 74 and 78 the limitations of claims 76 and 79 wherein the crosslinker is confined to sebacic acid and/or citric acid, thereby overcoming the closest prior art polymethacrylate crosslinkers of Graham et al. Patent No. 3,510,489 as suggested in the Final rejection mailed June 9, 2006 on page 3, the last paragraph. The cancellations of claims 87-91 overcomes the 35 U.S.C. 112, first paragraph, rejection. The 35 U.S.C. 102(b) rejection over Japanese Patent No. 5-132616 has been resolved by the cancellation of claims 87 and 90.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Sellers whose telephone number is (571) 272-1093. The examiner can normally be reached on Monday to Friday from 9:30 to 6:00. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866) 217-9197 (toll-free).

Robert Sellers
Primary Examiner

Art Unit 1712